Hematological Malignancies - Pursuit for the next blockbuster intensifies

Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity. Pipeline candidates classified as molecular targeted therapies, cytotoxic therapies and immunotherapeutic agents, may offer attractive therapeutic additions and Datamonitor's insight into their clinical and commercial potential is provided.

180 different pipeline candidates have been identified of which 22 are in late-phase development. These existing candidates have a forecast sales potential of up to $3.61 billion in the seven major pharmaceutical markets by 2016.

Agents holding strong commercial potential include Novartis' Gleevec-follow-on, Tasigna (nilotinib), and Genzyme's already approved purine analog Clolar (clofarabine) which is in development for acute myeloid leukemia. Other notable candidates include the anti-idiotype therapeutic vaccines and Biogen Idec's anti-CD23 MAb, lumiliximab.

Over 50% of the products are being investigated in acute and/or chronic leukemia. However, as an individual hematological subtype, NHL attracts the greatest attention from developers with 53 (29%) products in the pipeline despite the malignancy being comparatively well served by existing treatment regimens.

Read more...

• Obesity Drug Markets (14/10/2008)
• The Anti-Infectives Market Outlook to 2013 (14/10/2008)
• Respiratory Disorders (14/10/2008)

• Multiple Sclerosis (07/10/2008)
• Non-insulin antidiabetics (10/06/2008)
• Biosimilars-Regulatory Issues (27/05/2008)

• Biosimilars regulatory and development issues (20/05/2008)
• Monoclonal Antibodies Report Part II (19/05/2008)
• Acute Stroke (19/05/2008)
• Antifungals (16/05/2008)
• NNRTIs (16/05/2008)
• Non-Hodgkin's Lymphoma (16/05/2008)
• Multiple Myeloma (16/05/2008)
• Innovation in Drug Delivery (15/05/2008)
• Next-Generation Nutraceuticals (15/05/2008)

---